| scholarly article | Q13442814 |
| P50 | author | Josephine M. Forbes | Q17517073 |
| Richard O'Brien | Q57081567 | ||
| Andrew Murphy | Q80059346 | ||
| Merlin Thomas | Q56991969 | ||
| P2093 | author name string | M E Cooper | |
| A Hoang | |||
| M T Coughlan | |||
| D Sviridov | |||
| J P F Chin-Dusting | |||
| P2860 | cites work | Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes | Q22250887 |
| Apolipoprotein specificity for lipid efflux by the human ABCAI transporter | Q24290771 | ||
| Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells | Q57132532 | ||
| Glyoxalase System in Clinical Diabetes Mellitus and Correlation with Diabetic Complications | Q60786679 | ||
| Studies on the formation, separation, and characterization of cyanogen bromide fragments of human AI apolipoprotein | Q67299485 | ||
| Nonenzymatic Glycosylation of HDL and Impaired HDL-Receptor–Mediated Cholesterol Efflux | Q67913752 | ||
| Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure | Q70141654 | ||
| Efflux of intracellular versus plasma membrane cholesterol in HepG2 cells: different availability and regulation by apolipoprotein A-I | Q70890997 | ||
| Efflux of cellular cholesterol and phospholipid to apolipoprotein A-I mutants | Q71903339 | ||
| Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol | Q74299248 | ||
| Glycation of high-density lipoprotein does not increase its susceptibility to oxidation or diminish its cholesterol efflux capacity | Q74452472 | ||
| Role of oxidative stress in diabetic complications: a new perspective on an old paradigm | Q77804864 | ||
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I | Q28593742 | ||
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 | ||
| Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking | Q34180583 | ||
| ABCA1. The gatekeeper for eliminating excess tissue cholesterol. | Q34325121 | ||
| Diabetes and atherosclerosis: epidemiology, pathophysiology, and management | Q34646074 | ||
| A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. | Q34827947 | ||
| Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease | Q35866624 | ||
| Antiinflammatory properties of HDL. | Q35919164 | ||
| Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy | Q35950288 | ||
| Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? | Q36775094 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Nonenzymatic glycosylation of HDL resulting in inhibition of high-affinity binding to cultured human fibroblasts | Q38338966 | ||
| Why does diabetes increase atherosclerosis? I don't know! | Q39951404 | ||
| Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. | Q40485919 | ||
| Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages | Q40497096 | ||
| Leukocyte ABCA1 gene expression is associated with fasting glucose concentration in normoglycemic men. | Q40542354 | ||
| Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. | Q40763682 | ||
| Non-insulin dependent diabetes and reverse cholesterol transport | Q41131356 | ||
| Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation | Q42483749 | ||
| Differential regulation of apolipoprotein A-I/ATP binding cassette transporter A1-mediated cholesterol and phospholipid release | Q42807775 | ||
| Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products | Q43560094 | ||
| High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study | Q43985739 | ||
| Structure-function studies of apoA-I variants: site-directed mutagenesis and natural mutations. | Q44102355 | ||
| The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. | Q44575244 | ||
| Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression | Q44947212 | ||
| Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. | Q44953934 | ||
| High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients | Q44975110 | ||
| Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes | Q45028945 | ||
| Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells | Q46570578 | ||
| Circulating levels of nitrated apolipoprotein A-I are increased in type 2 diabetic patients | Q46592016 | ||
| Ability of serum to decrease cellular acylCoA:cholesterol acyl transferase activity predicts cardiovascular outcomes | Q46757559 | ||
| Apolipoprotein A-I lysine modification: effects on helical content, lipid binding and cholesterol acceptor activity | Q46958120 | ||
| Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. | Q46960352 | ||
| HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate | Q47951116 | ||
| P433 | issue | 8 | |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 1770-1779 | |
| P577 | publication date | 2007-06-20 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties | |
| P478 | volume | 50 |
| Q42127354 | A gel-based method for purification of apolipoprotein A-I from small volumes of plasma. |
| Q64258986 | A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function |
| Q60364605 | Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models |
| Q38741489 | Advanced glycation of high-density lipoprotein and the functionality of aldosterone release in type 2 diabetes |
| Q38623588 | Advances in high-density lipoprotein physiology: surprises, overturns, and promises |
| Q64277447 | Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus |
| Q91870367 | ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice |
| Q36683234 | ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity |
| Q30431517 | Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages |
| Q35610045 | Association of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary artery disease in patients with type 2 diabetes mellitus |
| Q35028691 | Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults |
| Q36496865 | Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties |
| Q37172727 | Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies |
| Q37430678 | Cholesterol Efflux Capacity of Apolipoprotein A-I Varies with the Extent of Differentiation and Foam Cell Formation of THP-1 Cells. |
| Q38620860 | Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways |
| Q37119309 | Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: consequences for atherosclerosis development |
| Q53099325 | Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. |
| Q26774903 | Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics |
| Q46626226 | Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. |
| Q37864145 | Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux. |
| Q35141623 | Glycoproteome of human apolipoprotein A-I: N- and O-glycosylated forms are increased in patients with acute myocardial infarction |
| Q42158972 | HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial. |
| Q37039076 | HDL: bridging past and present with a look at the future |
| Q58991979 | High Density Lipoprotein: Assembly, Structure, Cargo, and Functions |
| Q26750603 | High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties |
| Q37264429 | High density lipoprotein: a therapeutic target in type 2 diabetes |
| Q38965138 | High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. |
| Q35013804 | Hyperglycemia impairs atherosclerosis regression in mice |
| Q92662145 | Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity |
| Q57182351 | Linking diabetes and atherosclerosis |
| Q90854036 | Lysine glycation of apolipoprotein A-I impairs its anti-inflammatory function in type 2 diabetes mellitus |
| Q41908048 | Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease. |
| Q39387327 | Modified high-density lipoprotein modulates aldosterone release through scavenger receptors via extra cellular signal-regulated kinase and Janus kinase-dependent pathways |
| Q34255686 | Niacin: another look at an underutilized lipid-lowering medication |
| Q39192202 | Prooxidative effects of ambient pollutant chemicals are inhibited by HDL. |
| Q34256139 | Proprotein convertases in high-density lipoprotein metabolism |
| Q92611154 | Rethinking good cholesterol: a clinicians' guide to understanding HDL |
| Q38221965 | Role of HDL in those with diabetes |
| Q37851971 | Scavenger receptor class B, type I: a promising immunotherapy target. |
| Q42773416 | The causes and consequences of low levels of high density lipoproteins in patients with diabetes |
| Q42374104 | The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). |
| Q37978209 | The emerging role of HDL in glucose metabolism |
| Q35747737 | Type I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice |
| Q37119301 | Why is HDL functionally deficient in type 2 diabetes? |
Search more.